Compact GDTT1.8NAS12 DNA Vector for Safer Therapeutic Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy vectors face limitations such as the presence of antibiotic resistance genes, viral sequences, and excessive length, which compromise safety and efficiency in delivering therapeutic genes for conditions like Parkinson's disease, multiple sclerosis, and other neurological disorders.
Innovation Solution
Development of a gene therapy DNA vector, GDTT1.8NAS12, that lacks antibiotic resistance genes and viral sequences, with a size under 2600 bp, ensuring efficient cellular penetration and expression of therapeutic genes like DDC, IL10, IL13, IFNB1, TNFRSF4, TNFSF10, BCL2, HGF, and IL-2, suitable for industrial production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional gene therapy vectors are used, then therapeutic genes can be delivered, but the vectors contain antibiotic resistance genes and viral sequences that compromise safety
Solution Approach 1:
The patent removes harmful elements (antibiotic resistance genes and viral sequences) from the gene therapy vector, extracting only the essential therapeutic components to create a safer vector system
Solution Approach 2:
The patent converts the limitation of small vector size into a benefit by eliminating harmful sequences, thereby improving safety while maintaining the ability to deliver therapeutic genes
2Reliability
If gene therapy vectors include all necessary regulatory elements, then gene expression can be achieved, but the vector length becomes excessive reducing cellular penetration efficiency
Solution Approach 1:
The patent extracts only the essential regulatory elements needed for gene expression, removing redundant or excessive sequences to optimize vector length for cellular penetration
Solution Approach 2:
The patent optimizes the vector length parameter to under 2600 bp, changing the physical dimension to improve cellular uptake efficiency while maintaining functional capability
3Reliability
If vectors are optimized for safety by removing harmful sequences, then safety improves, but the complexity of vector design and production increases
Solution Approach 1:
The patent segments the vector design into modular components (backbone, promoter, therapeutic gene, terminator), making the simplified vector easier to construct and produce despite safety optimizations
Solution Approach 2:
The patent creates a universal vector backbone that can accommodate multiple different therapeutic genes, reducing overall design complexity by reusing the same safe framework for different applications
Data Source
AI summary
Proposed is a gene-therapy DNA vector, based on gene-therapy DNA vector GDTT1.8NAS12, for treating diseases characterized by progressive pathological changes in the nerve tissue structure and neuron function, including neuron death, which are associated with genetic factors, including mutations in genes coding for proteins critical to the normal functioning of the neurons, inter alia Huntington's disease and hereditary forms of amyotrophic lateral sclerosis, as well as with misfolding of the tertiary structure of proteins, inter alia Parkinson's disease and Alzheimer's disease, damage to the central nervous system, disruption of the oxygen supply to the brain or spinal cord, defective neuronal energy metabolism and axonal transport, or autoimmune demyelinating processes, inter alia multiple sclerosis. As a result of the limited size of the vector part GDTT1.8NAS12, which is not greater than 2600 bp, each of the proposed gene-therapy DNA vectors is capable of effectively penetrating into human and animal cells and expressing the target gene cloned within it.